Depression is common and there are effective treatment options to help you feel better. We're going to talk about the ...

SAD is a clinical form of depression that follows a seasonal pattern. Most people experience its onset in late autumn or ...

Titusville: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved CAPLYTA ...

Depression is one of the most widespread mental health disorders worldwide, characterized by persistent feelings of sadness, a loss of interest in everyday activities, dysregulated sleep or eating ...

Caplyta’s most recent FDA approval is based on positive results from two Phase III clinical trials: Study 501 (NCT04985942) and Study 502 (NCT05061706). Both studies met their primary endpoint and key ...

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

Thriveworks reports seasonal depression peaks in the third week of November, with symptoms affecting cities that experience ...

Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...

Creatine supplementation may modestly reduce depressive symptoms, but the effect is small, uncertain, and likely influenced ...

The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.

Ketogenic diets may modestly improve depressive symptoms, especially with ketone monitoring and very low-carbohydrate interventions. Ketogenic diets were linked to modest reductions in depressive ...